RecruitingNCT07148193

Quality of Life and Medical Care of Long-term Sarcoma Survivors in Germany (PROSa+)

Understanding Long-Term Sarcoma Survivorship: Risk Profiles, Outcomes and Unmet Needs - A Joint Project of Research, Sarcoma Centres and Patient Experts (PROSa+)


Sponsor

Technische Universität Dresden

Enrollment

1,600 participants

Start Date

Nov 28, 2025

Study Type

OBSERVATIONAL

Conditions

Summary

The study PROSa+ aims to assess patient-reported outcomes (PROs), patient-reported experiences (PREs), and the socioeconomic situation of long-term sarcoma survivors (≥ 5 years post-diagnosis, with or without active disease) in Germany. The mixed-methods research design includes a multicenter observational study with a cross-sectional questionnaire survey involving 1,600 participants (paper, online), qualitative interviews with up to 60 participants, and longitudinal analyses combining data from existing sarcoma registries and the previous PROSa study conducted between 2017 and 2020.


Eligibility

Min Age: 18 Years

Inclusion Criteria4

  • Diagnosis of sarcoma according to the International Classification of Diseases for Oncology (ICD-O) and World Health Organization (WHO) classification, including soft tissue sarcoma, bone sarcoma, and GIST
  • At least 5 years since initial sarcoma diagnosis
  • With or without active disease
  • Age ≥18 years at the time of study participation

Exclusion Criteria2

  • Diagnosis of Desmoid tumors
  • Inability to complete a structured questionnaire (e.g., due to insufficient German language skills, cognitive impairment, dementia)

Interventions

OTHERNo intervention (observational study)

No intervention (observational study)


Locations(5)

Technical University Dresden

Dresden, Saxony, Germany

University Hospital Essen

Essen, Germany

NCT Heidelberg

Heidelberg, Germany

Sarcoma Center Mannheim

Mannheim, Germany

Deutsche Sarkom-Stiftung

Wölfersheim, Germany

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07148193


Related Trials